STL ADDS 93 PATENTS TO ITS CREDIT IN FY20
STL recorded significant growth in its patent portfolio. From world-class universal fibre to AI-based network mapping to drone-based deployment to access solutions, our patents are winning at every step. STL is also an active member of the Open Innovation Network (OIN), a global patent pool of innovative tech companies and works with leading research institutions like Rutgers, MIT and IIT Madras.
Read MoreWatch Now
STL AND VVDN JOIN HANDS TO EMPOWER THE EDGE
With VVDN’s experience in radio manufacturing and STL’s focus on edge solutions, both the companies will collectively ideate, design, and develop innovative solutions to support critical infrastructure for 5G. The solutions will enable operators worldwide to address multiple deployment use cases with a faster time to market.
Read More
CONNECTING 17K ISLANDS ACROSS INDONESIA STL enabled a highly secure and reliable fibre optic infrastructure in partnership with PT. Mora Telematika, largest network access provider in Indonesia. This is helping Indonesian people work and learn from home during these challenging times.
Watch Now
ENABLING SEAMLESS #WFHDuring unprecedented situations like COVID-19, we are making our dWiFi platform available free to our customers in Europe till normalcy is restored. We are in the process of offering a free trial version of our product dWiFi which solves the problem of balancing the load between telecom and broadband networks.
Read More
TRAINING OVER 100k YOUTH ON COVID19 AWARENESSSTL forms Project Savdhaan, a special initiative to train over 100k youth on COVID-19 awareness. STL Academy conducted COVID-19 online awareness drive in association with Telecom Sector Skill Council (TSSC), Infrastructure Equipment Skill Council (IESC) and Telangana Academy for Skill and Knowledge (TASK).
The workshop was broadcasted on 27th March 2020 from Hyderabad and hosted live for everyone. Medical experts conducted workshops covering social distancing and community-based measures to mitigate the spread of COVID-19.
Read More
Please wait while you are redirected to the right page...
